MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Drugs.com - Clinical Trials' source. Thu, 09 Feb 2012 01:31:30 +0100 http://www.medworm.com/index.php?rid=5669417&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F_J93eBIStac%2Fconclusive-results-regulatory-toxicology-studies-gft505-13041.html   ?? The complete regulatory toxicology package of GFT505 confirms its safety in long-term treatment. ? Lille (France), Cambridge (Massachusetts, United States), February 8th, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669417 Wed, 08 Feb 2012 19:30:14 +0100 5669417 http://www.medworm.com/index.php?rid=5669418&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fn8Ro-L-0IMo%2Fhalting-bone-building-osteoporosis-cuts-risk-additional-atypical-femur-fracture-13038.html SAN FRANCISCO, Feb. 8, 2012 /PRNewswire-USNewswire/ -- There is growing evidence that supports an association between atypical fractures of the femur – a rare break of the thigh bone, typically without trauma – and the use of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669418 Wed, 08 Feb 2012 16:02:52 +0100 5669418 http://www.medworm.com/index.php?rid=5669419&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FXz93mBzVmtQ%2Ffour-year-data-phase-2-trial-genzyme-gaucher-oral-compound-suggest-sustained-continued-improvement-13039.html Phase 3 Studies of Eliglustat Tartrate Fully Enrolled CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 8, 2012 - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today four-year follow-up data from patients enrolled in the phase 2... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669419 Wed, 08 Feb 2012 16:02:23 +0100 5669419 http://www.medworm.com/index.php?rid=5669420&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FczUSDml6u2g%2Favanir-pharmaceuticals-announces-publication-phase-iii-study-results-showing-efficacy-safety-avp-13040.html Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain ALISO VIEJO, Calif., Feb. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc.... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669420 Wed, 08 Feb 2012 16:02:21 +0100 5669420 http://www.medworm.com/index.php?rid=5669421&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FAGIt3dRVqaU%2Fforest-laboratories-inc-gedeon-richter-plc-announce-positive-phase-iii-results-investigational-13037.html NEW YORK & BUDAPEST, Hungary--(BUSINESS WIRE)--Feb 8, 2012 - Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from a Phase III clinical trial of cariprazine (RGH-188), an investigational... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669421 Wed, 08 Feb 2012 13:02:42 +0100 5669421 http://www.medworm.com/index.php?rid=5669422&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FZUuoZj7mKsw%2Fpivotal-study-published-jama-confirms-potential-novartis-candidate-vaccine-bexsero-help-protect-13036.html     Data previously presented at ESPID annual meeting add to the body of evidence showing that Bexsero can help protect all vulnerable age groups     Study including more than 1,800 infants showed Bexsero induces robust immune... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669422 Wed, 08 Feb 2012 12:02:55 +0100 5669422 http://www.medworm.com/index.php?rid=5669423&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F1AtLx916p4U%2Fomeros-provides-update-ongoing-oms302-phase-3-clinical-trial-13035.html SEATTLE, Feb. 7, 2012  /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that recent positive clinical developments have allowed it to revise the planned analysis for its ongoing Phase 3 clinical trial evaluating OMS302, which... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669423 Tue, 07 Feb 2012 23:02:17 +0100 5669423 http://www.medworm.com/index.php?rid=5669424&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F1Y7GrDRkAmU%2Fjennerex-publishes-data-jx-594-cancer-targeting-mechanisms-13034.html -- JX-594 Selectivity is Multi-Mechanistic, Driven by Genetic Traits Common in Solid Tumors -- SAN FRANCISCO, Feb. 7, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669424 Tue, 07 Feb 2012 22:02:08 +0100 5669424 http://www.medworm.com/index.php?rid=5669425&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F-w-vvQ2hlyQ%2Fcannabis-science-awaits-full-biopsy-report-newest-series-photos-shows-cancer-lesion-evidently-13033.html DENVER--(BUSINESS WIRE)--Feb 7, 2012 - Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to present the newest set of photographs showing evidence that the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669425 Tue, 07 Feb 2012 19:02:30 +0100 5669425 http://www.medworm.com/index.php?rid=5669426&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FgBeEOdLyIk4%2Fthrasos-collaborators-publish-nature-medicine-research-article-detailing-potential-approach-kidney-13031.html Preclinical Research Validates Role of BMP Pathway in Treating Progressive Kidney Disease and Potential for Thrasos' Compounds to Selectively Target the Pathway MONTREAL--(BUSINESS WIRE)--Feb 7, 2012 - Thrasos today announced that the journal... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669426 Tue, 07 Feb 2012 18:02:29 +0100 5669426 http://www.medworm.com/index.php?rid=5669427&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FqJ--zZgXqV8%2Fanacor-pharmaceuticals-announces-positive-preliminary-results-two-safety-studies-an2728-updates-13032.html PALO ALTO, Calif.--(BUSINESS WIRE)--Feb 7, 2012 - Anacor Pharmaceuticals (NASDAQ:ANAC) announced today positive preliminary results from two safety studies of AN2728 - a maximal use systemic exposure (MUSE) study in psoriatic patients and a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669427 Tue, 07 Feb 2012 18:02:04 +0100 5669427 http://www.medworm.com/index.php?rid=5669428&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FNxeRB0mlye0%2Fnew-study-evaluates-cialis-parallel-tamsulosin-men-signs-suggestive-benign-prostatic-hyperplasia-13030.html Phase III study met primary endpoint INDIANAPOLIS, Feb. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that a Phase III study, published online by European Urology, showed both Cialis® (tadalafil) and tamsulosin... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669428 Tue, 07 Feb 2012 16:02:09 +0100 5669428 http://www.medworm.com/index.php?rid=5669429&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fd8sqGGTwp0Y%2Fmerck-announces-top-line-results-tra-2p-study-vorapaxar-13029.html Company Will Review Data FromTRA-2P and TRACER With External Experts to Inform Next Steps WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 7, 2012 - Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced the top-line... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669429 Tue, 07 Feb 2012 13:02:36 +0100 5669429 http://www.medworm.com/index.php?rid=5669430&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FTQzDZWZ2DiM%2Fclinical-results-aduro-s-phase-1-trials-published-clinical-cancer-research-13028.html BERKELEY, Calif.--(BUSINESS WIRE)--Feb 7, 2012 - Aduro BioTech, Inc. is pleased to announce the publication of two therapeutic cancer vaccine Phase 1 studies in Clinical Cancer Research (volume 18(3), pages 1-11). In the article, which was... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669430 Tue, 07 Feb 2012 11:02:18 +0100 5669430 http://www.medworm.com/index.php?rid=5669431&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FbRpuHCU5fmI%2Flubiprostone-meets-primary-endpoint-phase-3-clinical-trial-opioid-induced-bowel-dysfunction-obd-13026.html Aim to File for Approval of Lubiprostone as First Oral Drug for Prescription-based Treatment of OBD Anticipate sNDA Filing in US in First Half of 2012 – Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A.,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669431 Mon, 06 Feb 2012 20:02:57 +0100 5669431 http://www.medworm.com/index.php?rid=5669432&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fc36BPMus-v0%2Fnejm-features-two-positive-pivotal-trials-hra-pharma-compound-ulipristal-acetate-uterine-fibroids-13027.html   Paris, February 2, 2012 - The New England Journal of Medicine (NEJM) today published results of two phase III clinical trials introducing ulipristal acetate, HRA Pharma proprietary compound, as an effective pre-operative treatment of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669432 Mon, 06 Feb 2012 20:02:34 +0100 5669432 http://www.medworm.com/index.php?rid=5669433&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F6irTiSQ9lZo%2Faeterna-zentaris-reports-updated-phase-1-trial-results-aezs-108-castration-taxane-resistant-13025.html QUÉBEC CITY, Feb. 3, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:?AEZ) (the "Company") today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669433 Mon, 06 Feb 2012 19:02:54 +0100 5669433 http://www.medworm.com/index.php?rid=5669434&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FRvYvGHM5FFk%2Fcombined-asthma-therapy-shown-reduce-attacks-13024.html DETROIT, Feb. 6, 2012 – A Henry Ford Hospital study has found that using two types of common asthma medications in combination reduces severe asthma attacks.   Researchers say using long-acting beta-agonists (LABAs) in fixed-dose combination... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669434 Mon, 06 Feb 2012 18:02:44 +0100 5669434 http://www.medworm.com/index.php?rid=5669435&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FPhiAgrZ9mM0%2Fnovel-shows-significant-promise-treating-severe-stroke-patients-13023.html Remedy Pharmaceutical's drug may finally hold the answer to solving this medical dilemma NEW YORK--(BUSINESS WIRE)--Feb 6, 2012 - Each year, over 700,000 people in the United States suffer a stroke. For most, medical science can do very little.... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669435 Mon, 06 Feb 2012 17:02:22 +0100 5669435 http://www.medworm.com/index.php?rid=5669436&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FqR_lDMrTeDg%2Fargos-therapeutics-announces-new-data-demonstrating-prolonged-overall-survival-phase-2-study-13022.html -Results Support Planned, Randomized Phase 3 ADAPT Study-     DURHAM, N.C., Feb. 4, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that updated results from an open label Phase 2 study of its Arcelis immunotherapy, AGS-003, in... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5669436 Mon, 06 Feb 2012 12:02:09 +0100 5669436 http://www.medworm.com/index.php?rid=5661353&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FWIgmSqF8NBE%2Fstudy-finds-no-between-aggrenox-aspirin-extended-release-dipyridamole-25mg-200mg-capsules-13021.html RIDGEFIELD, Conn., Feb. 3, 2012 /PRNewswire/ -- Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox® (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5661353 Fri, 03 Feb 2012 17:02:33 +0100 5661353 http://www.medworm.com/index.php?rid=5661354&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FCBZ1uJsQpVw%2Ftriglyceride-levels-found-predict-stroke-older-women-13020.html     A Stronger Link than Cholesterol Levels to Ischemic Stroke BRONX, N.Y., Feb. 2, 2012 /PRNewswire-USNewswire/ -- In a surprising finding with significant implications for older women, researchers at Albert Einstein College of Medicine of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5661354 Fri, 03 Feb 2012 14:02:47 +0100 5661354 http://www.medworm.com/index.php?rid=5661355&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Ffkmt9Up4W-Q%2Fyoung-children-exposed-anesthesia-multiple-times-show-elevated-rates-adhd-13019.html ROCHESTER, Minn.--(BUSINESS WIRE)--Feb 2, 2012 - Mayo Clinic researchers have found that multiple exposures to anesthesia at a young age are associated with higher rates of attention-deficit/hyperactivity disorder (ADHD). VIDEO ALERT:... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5661355 Fri, 03 Feb 2012 14:02:23 +0100 5661355 http://www.medworm.com/index.php?rid=5661356&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FPwmhIAITafY%2Fstudy-published-neuro-oncology-journal-shows-brain-tumor-eradication-prolonged-survival-mice-13017.html     SAN DIEGO, Feb. 3, 2012 /PRNewswire/ -- Tocagen Inc. today announced the publication of data showing the company's investigational treatment for high grade glioma eradicates brain tumors and provides a dramatic survival benefit in mouse... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5661356 Fri, 03 Feb 2012 13:02:55 +0100 5661356 http://www.medworm.com/index.php?rid=5661357&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FZSnyoGDQ50o%2Faeterna-zentaris-reports-updated-phase-1-trial-results-aezs-108-castration-taxane-resistant-13018.html QUÉBEC CITY, Feb. 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5661357 Fri, 03 Feb 2012 13:02:53 +0100 5661357 http://www.medworm.com/index.php?rid=5661358&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F-qRDlWYaJG4%2Facorda-therapeutics-presents-preclinical-data-showing-dalfampridine-improves-motor-function-chronic-13015.html First ever data to demonstrate improvement in motor function following stroke with oral drug treatment initiated several weeks after event HAWTHORNE, N.Y.--(BUSINESS WIRE)--Feb 3, 2012 - Acorda Therapeutics, Inc. (Nasdaq: ACOR) presented... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5661358 Fri, 03 Feb 2012 12:02:53 +0100 5661358 http://www.medworm.com/index.php?rid=5661359&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FIWxuP7d0pXQ%2Fcabozantinib-shows-encouraging-activity-heavily-pretreated-patients-advanced-renal-cell-carcinoma-13016.html 14.7 months median progression free survival 28% confirmed partial response rate & 72% disease control rate at week 16 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today reported preliminary data from a cohort... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5661359 Fri, 03 Feb 2012 11:02:22 +0100 5661359 http://www.medworm.com/index.php?rid=5651525&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FWgBDtEW21zo%2Fdiamyd-medical-s-phase-iii-study-published-new-england-journal-medicine-13013.html STOCKHOLM--(BUSINESS WIRE)--Feb 2, 2012 - Regulatory News: An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy Diamyd® has been published in the scientific journal the New England... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651525 Thu, 02 Feb 2012 20:34:04 +0100 5651525 http://www.medworm.com/index.php?rid=5651526&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FwpRfC_FBhp8%2Flubiprostone-meets-primary-endpoint-phase-3-clinical-trial-opioid-induced-bowel-dysfunction-obd-13012.html Aim to File for Approval of Lubiprostone as First Oral Drug for Prescription-based Treatment of OBD Anticipate sNDA Filing in US in First Half of 2012 BETHESDA, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--Feb 2, 2012 - Sucampo Pharmaceuticals, Inc.... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651526 Thu, 02 Feb 2012 20:02:21 +0100 5651526 http://www.medworm.com/index.php?rid=5651527&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FEaeUmMRS4ys%2Fcompugen-cancer-target-results-demonstrate-significant-potential-cancer-immunotherapy-13014.html Expression levels of CGEN-15001T on various solid, hematological cancer cells and immune cells combined with its immunomodulatory activities support its potential use as a powerful drug target for cancer immunotherapy TEL AVIV, Israel--(BUSINESS... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651527 Thu, 02 Feb 2012 20:02:16 +0100 5651527 http://www.medworm.com/index.php?rid=5651528&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FE6zWujUzHe8%2Finternational-phase-trial-results-recombinant-fusion-protein-linking-coagulation-factor-ix-albumin-13011.html Results from the Phase I of the PROLONG-9FP trial program demonstrate clinical safety and improved pharmacokinetics of rIX-FP compared to current treatment options St. Gallen, Switzerland — 02 February 2012 CSL Behring today announced the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651528 Thu, 02 Feb 2012 19:02:13 +0100 5651528 http://www.medworm.com/index.php?rid=5651529&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FPnDMxoWFxiQ%2Fcannabis-science-reports-success-4th-brand-new-self-administering-cancer-patient-13009.html DENVER--(BUSINESS WIRE)--Feb 2, 2012 - Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to introduce a 4th cancer patient with basal cell... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651529 Thu, 02 Feb 2012 16:02:42 +0100 5651529 http://www.medworm.com/index.php?rid=5651530&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FMbKttI7EMVQ%2Finternational-phase-trial-results-recombinant-fusion-protein-linking-coagulation-factor-ix-albumin-13010.html Results from the Phase I of the PROLONG-9FP trial program demonstrate clinical safety and improved pharmacokinetics of rIX-FP compared to current treatment options ST. GALLEN, Switzerland, Feb. 2, 2012 /PRNewswire/ -- CSL Behring today announced... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651530 Thu, 02 Feb 2012 14:02:23 +0100 5651530 http://www.medworm.com/index.php?rid=5651531&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FvelbNAWKb-k%2Fclinical-data-ogx-427-presented-asco-2012-genitourinary-cancers-symposium-provide-ongoing-evidence-13008.html OncoGenex Announces Plans to Initiate a Phase 2 Study of OGX-427 in Combination with Zytiga® (abiraterone) in Castrate-Resistant Prostate Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 2, 2012 /CNW/ - OncoGenex Pharmaceuticals,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651531 Thu, 02 Feb 2012 13:02:27 +0100 5651531 http://www.medworm.com/index.php?rid=5651533&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FkEQdWUHLyVQ%2Fphase-1-study-ogx-427-presented-asco-2012-genitourinary-cancers-symposium-shows-early-evidence-13006.html Data Support Ongoing Phase 2 Study in Metastatic Bladder Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 2, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today preliminary results from an... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651533 Thu, 02 Feb 2012 13:02:02 +0100 5651533 http://www.medworm.com/index.php?rid=5651534&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FVgvqV2eOKzs%2Fnih-launches-trials-evaluate-cpr-after-sudden-cardiac-arrest-13005.html The National Institutes of Health has launched two multi-site clinical trials to evaluate treatments for out-of-hospital cardiac arrest. One will compare continuous chest compressions (CCC) combined with pause- free rescue breathing to... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651534 Wed, 01 Feb 2012 20:02:53 +0100 5651534 http://www.medworm.com/index.php?rid=5651535&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FAi4aoE1C8Cw%2Fthermogenesis-provides-update-res-q-clinical-evaluations-leading-stem-cell-therapy-conference-13004.html INITIAL DATA SHOW POSITIVE OUTCOMES IN TREATING CRITICAL LIMB ISCHEMIA AND LONG BONE FRACTURES   RANCHO CORDOVA, Calif., Feb. 1, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651535 Wed, 01 Feb 2012 19:02:56 +0100 5651535 http://www.medworm.com/index.php?rid=5651536&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FR1jsuCsrJ3g%2Fab-science-reports-positive-clinical-study-data-masitinib-significantly-extends-overall-survival-13003.html PARIS--(BUSINESS WIRE)--Feb 1, 2012 - Regulatory News: AB Science SA (Paris:AB) (NYSE Euronext - FR0010557264 - AB) today announced encouraging results from a phase 2 study with its investigational drug, masitinib, in... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651536 Wed, 01 Feb 2012 17:02:52 +0100 5651536 http://www.medworm.com/index.php?rid=5651537&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FOniepy32858%2Faethlon-medical-reports-immediate-rapid-virologic-responses-hepatitis-c-hcv-patients-receiving-13002.html SAN DIEGO, Feb. 1, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651537 Wed, 01 Feb 2012 13:02:48 +0100 5651537 http://www.medworm.com/index.php?rid=5651538&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FNGxU_sg14yo%2Fexperimental-neurology-journal-brainstorm-s-nurown-stem-cell-technology-shows-promise-treating-13001.html Positive Preclinical Results Published in the Experimental Neurology Journal NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--Feb 1, 2012 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651538 Wed, 01 Feb 2012 13:02:18 +0100 5651538 http://www.medworm.com/index.php?rid=5651539&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FrSXGEaCqRU0%2Fmedivation-astellas-announce-positive-results-phase-3-affirm-trial-mdv3100-prostate-cancer-patients-12999.html SAN FRANCISCO, CA and TOKYO -- (MARKET WIRE) -- 01/31/12 -- Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced positive results on all efficacy endpoints from the Phase 3 AFFIRM trial of the investigational drug... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651539 Wed, 01 Feb 2012 11:02:35 +0100 5651539 http://www.medworm.com/index.php?rid=5651540&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FOh62xSppjNU%2Fdendreon-announces-presentation-provenge-data-asco-2012-genitourinary-cancers-symposium-13000.html SEATTLE--(BUSINESS WIRE)--Jan 31, 2012 - January 31, 2012 – Dendreon Corporation (NASDAQ: DNDN) today announced the following PROVENGE® data will be presented at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651540 Wed, 01 Feb 2012 11:02:05 +0100 5651540 http://www.medworm.com/index.php?rid=5651541&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F-ONjoWrGhuQ%2Fargos-therapeutic-arcelis-immunotherapy-ags-003-combination-sunitinib-shows-statistically-12998.html -High Resolution Immune Monitoring Analysis Shows AGS-003 in Combination With Sunitinib Overcomes Immuno-Suppressive Environment of RCC and Induces Tumor-Specific Multi-Functional Memory Cytotoxic T Lymphocytes (CTL) in Phase 2 Study- DURHAM,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651541 Tue, 31 Jan 2012 23:01:56 +0100 5651541 http://www.medworm.com/index.php?rid=5651542&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FyTt0mUr36Lg%2Fampio-pharmaceuticals-inc-announces-statistically-significant-improvement-pain-relief-lead-product-12997.html GREENWOOD VILLAGE, Colo., Jan. 31, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651542 Tue, 31 Jan 2012 23:01:12 +0100 5651542 http://www.medworm.com/index.php?rid=5651543&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FbRI5GjkunxM%2Finovio-pharmaceuticals-moves-closer-universal-influenza-vaccine-demonstrating-protective-immune-12996.html Cross-strain immune responses generated by Inovio's novel SynCon® vaccine design in additional subtypes build on prior positive data from H5N1 and H1N1 subtypes   Download image BLUE BELL, Pa., Jan. 31, 2012 /PRNewswire/ --... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651543 Tue, 31 Jan 2012 23:01:08 +0100 5651543 http://www.medworm.com/index.php?rid=5651544&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FFGRZ_Ywi6i4%2Fhti-501-data-support-commencement-phase-2-portion-clinical-trial-12995.html Subcutaneous Administration of Conditionally Active Recombinant Human Cathepsin Was Well Tolerated   Download image SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today presented interim results from the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651544 Tue, 31 Jan 2012 21:01:08 +0100 5651544 http://www.medworm.com/index.php?rid=5651545&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F5uxH9VnWNeU%2Finovio-pharmaceuticals-moves-closer-universal-influenza-vaccine-demonstrating-protective-immune-12993.html Cross-strain immune responses generated by Inovio’s novel SynCon® vaccine design in additional subtypes build on prior positive data from H5N1 and H1N1 subtypes BLUE BELL, PA – January 31, 2012 -- Inovio Pharmaceuticals, Inc. (NYSE... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651545 Tue, 31 Jan 2012 20:01:32 +0100 5651545 http://www.medworm.com/index.php?rid=5651546&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FzURSRsRRjTM%2Fvical-presents-case-study-successful-design-allovectin-phase-3-melanoma-trial-12994.html WASHINGTON, Jan. 30, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company will present a case study of its Allovectin® Phase 3 trial at the Phacilitate Cell & Gene Therapy Forum 2012 (Washington – January... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651546 Tue, 31 Jan 2012 20:01:18 +0100 5651546 http://www.medworm.com/index.php?rid=5651547&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F_jkv1zo81F4%2Fbiorestorative-therapies-signs-license-agreement-stem-cell-disc-spine-procedure-12991.html Patient Treatments of Bulging and Herniated Discs Show Promising Results Closing of License Grant Scheduled for March 2012 JUPITER, Fla., Jan. 31, 2012 /PRNewswire/ -- BioRestorative Therapies, Inc. (OTCQB: BRTX) ("BRT") today announced that it... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651547 Tue, 31 Jan 2012 16:01:33 +0100 5651547 http://www.medworm.com/index.php?rid=5651548&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FcoLgubD0BwI%2Fexciting-data-remedy-pharmaceutical-sponsored-stroke-trial-presented-2012-international-stroke-12992.html Senator Kirk's Stroke Shines A Light On The Need For a Cure NEW YORK--(BUSINESS WIRE)--Jan 31, 2012 - On February 2 in New Orleans, Dr. Kevin Sheth of the University of Baltimore Medical Center will address an audience at the International... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651548 Tue, 31 Jan 2012 13:01:35 +0100 5651548 http://www.medworm.com/index.php?rid=5651549&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FhZeKgVxJg8o%2Finherited-risk-factors-childhood-leukemia-more-common-hispanic-patients-12990.html         Results from a St. Jude Children's Research Hospital and the Children's Oncology Group study pinpoint genetic basis for increased leukemia risk facing Hispanic children and provide new hope for closing survival gap MEMPHIS,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651549 Mon, 30 Jan 2012 21:01:22 +0100 5651549 http://www.medworm.com/index.php?rid=5651550&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FYrjyiz9noBo%2Fvgx-100-identified-potential-new-therapy-improving-corneal-graft-survival-12988.html - Data published in the scientific journal Investigative Ophthalmology & Visual Science generated by investigators at the Schepens Eye Research Institute led by Harvard University Professor Reza Dana.   MELBOURNE, Australia, January 30, 2012,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651550 Mon, 30 Jan 2012 20:01:18 +0100 5651550 http://www.medworm.com/index.php?rid=5651551&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F2yLGnkMcMm0%2Fresults-nono-inc-sponsored-phase-2-clinical-trial-procedurally-induced-strokes-announced-12989.html Principal Investigator of NoNO Inc.-sponsored Trial Announces Promising Results of a Stroke Drug Study in Patients Subjected to Embolic Strokes at the International Stroke Conference, February 2, 2012 TORONTO, Jan. 30, 2012... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651551 Mon, 30 Jan 2012 20:01:03 +0100 5651551 http://www.medworm.com/index.php?rid=5651552&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FGMzSq_ToBDE%2Fsynageva-biopharma-highlights-key-data-presentations-upcoming-lysosomal-network-ldn-world-symposium-12987.html - Multiple abstracts selected for oral presentations on February 8-10th in San Diego, CA - LEXINGTON, Mass.--(BUSINESS WIRE)--Jan 30, 2012 - Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651552 Mon, 30 Jan 2012 18:01:40 +0100 5651552 http://www.medworm.com/index.php?rid=5651553&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FQanYVsYfQ6I%2Fcardium-presents-new-generx-findings-2012-annual-gene-cell-therapy-forum-12986.html New insights Support Generx Angiogenic Therapy Phase 3 Registration Clinical Study for Patients with Coronary Artery Disease SAN DIEGO, Jan. 30, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported on new insights and... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651553 Mon, 30 Jan 2012 17:01:56 +0100 5651553 http://www.medworm.com/index.php?rid=5651554&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FYXPF8hNGbJc%2Fimmunocellular-therapeutics-deliver-presentation-cancer-stem-cells-prestigious-immunotherapy-12985.html LOS ANGELES--(BUSINESS WIRE)--Jan 30, 2012 - ImmunoCellular Therapeutics, Ltd.(“ImmunoCellular” or the Company) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651554 Mon, 30 Jan 2012 17:01:04 +0100 5651554 http://www.medworm.com/index.php?rid=5651556&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FiY4e8DHzNI8%2Fseattle-genetics-millennium-report-data-phase-trial-adcetris-front-line-mature-t-cell-lymphomas-12984.html -Phase III Trial Planned in Front-line Mature T-Cell Lymphomas- SAN FRANCISCO--(BUSINESS WIRE)--Jan 26, 2012 - Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company today announced interim results from 32 patients... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651556 Mon, 30 Jan 2012 15:01:34 +0100 5651556 http://www.medworm.com/index.php?rid=5651555&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F0Oevk7BvyKc%2Fcannabis-science-presents-newest-photographs-3rd-cancer-patient-show-cancer-tumors-dying-areas-now-12980.html DENVER--(BUSINESS WIRE)--Jan 30, 2012 - Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to share new photographs from this cancer patient with severe... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651555 Mon, 30 Jan 2012 15:01:34 +0100 5651555 http://www.medworm.com/index.php?rid=5651557&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FKAzEwbcJfo8%2Finfinity-reports-update-phase-2-study-saridegib-plus-gemcitabine-patients-metastatic-pancreatic-12983.html – Infinity Stops Phase 2 Study Following Preliminary Analysis Showing Trial Would Not Meet Primary Endpoint of Overall Survival – – No Unexpected Adverse Events Observed in Study – – Phase 2 Trials Exploring Distinct... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651557 Mon, 30 Jan 2012 15:01:32 +0100 5651557 http://www.medworm.com/index.php?rid=5651558&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FmbycwAyCpYw%2Fcompugen-presents-three-product-candidates-autoimmune-diseases-immunotherapeutics-immunomonitoring-12981.html Presentation demonstrates the therapeutic effects of CGEN-15001, CGEN-15021 and CGEN-15091 in disease animal models of rheumatoid arthritis and multiple sclerosis SAN DIEGO--(BUSINESS WIRE)--Jan 30, 2012 - Speaking today at the 4th... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651558 Mon, 30 Jan 2012 14:01:30 +0100 5651558 http://www.medworm.com/index.php?rid=5651559&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FFUh1C5EGyQQ%2Fjuventas-therapeutics-reports-one-year-data-phase-heart-failure-clinical-trial-12982.html CLEVELAND, Jan. 30, 2012 /PRNewswire-USNewswire/ -- Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease. The Company's lead product, JVS-100, encodes... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5651559 Mon, 30 Jan 2012 14:01:11 +0100 5651559 http://www.medworm.com/index.php?rid=5631189&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FyqpuMm344LQ%2Fchimerix-announces-presentation-final-data-cmx001-phase-2-trial-prophylaxis-cytomegalovirus-12979.html Abstract Receives "BEST ABSTRACTS AWARD FOR CLINICAL RESEARCH" at 2012 BMT Tandem Meetings on February 3rd, 2012 RESEARCH TRIANGLE PARK, N.C., Jan. 25, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing novel... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5631189 Wed, 25 Jan 2012 18:01:06 +0100 5631189 http://www.medworm.com/index.php?rid=5631190&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fc9TMz2k0SSY%2Flifesci-advisors-publishes-jakafi-survey-results-12975.html Survey Predicts Peak US Sales from $600-$700 million for JAKAFI Full Results Available for Free Download at www.lifesciadvisors.com/marketresearch/ NEW YORK, Jan. 24, 2012 /PRNewswire/ -- LifeSci Advisors, LLC, a leading provider of investment... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5631190 Tue, 24 Jan 2012 17:01:18 +0100 5631190 http://www.medworm.com/index.php?rid=5631191&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FU7ja04PLIA0%2Frecent-study-reveals-benefits-women-dhea-hormone-12976.html CHARLESTON, S.C., Jan. 24, 2012 /PRNewswire/ -- Leading age management facility, Cenegenics Carolinas, located in Charleston (age management Charleston) and Charlotte (age management Charlotte) is encouraged by a recent study suggesting low doses... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5631191 Tue, 24 Jan 2012 16:01:57 +0100 5631191 http://www.medworm.com/index.php?rid=5631192&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F-HEi7db40Rw%2Flifesci-advisors-publishes-jakafi-survey-results-12977.html Survey Predicts Peak US Sales from $600-$700 million for JAKAFI Full Results Available for Free Download at www.lifesciadvisors.com/marketresearch/ NEW YORK, Jan. 24, 2012 /PRNewswire/ -- LifeSci Advisors, LLC, a leading provider of investment... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5631192 Tue, 24 Jan 2012 16:01:55 +0100 5631192 http://www.medworm.com/index.php?rid=5631193&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FG_YSzfrWqLc%2Fcannabis-science-updates-latest-remarkable-follow-up-photographs-received-3rd-cancer-patient-12978.html DENVER--(BUSINESS WIRE)--Jan 24, 2012 - Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to announce new remarkable photographic updates of the 3rd... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5631193 Tue, 24 Jan 2012 15:01:32 +0100 5631193 http://www.medworm.com/index.php?rid=5621705&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FXTSqcCLg_ek%2Fsenior-management-neostem-subsidiaries-invited-speak-seventh-international-conference-cell-therapy-12974.html NEW YORK, Jan. 23, 2012 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced that its Chief Medical Officer,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5621705 Mon, 23 Jan 2012 20:01:47 +0100 5621705 http://www.medworm.com/index.php?rid=5621706&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FX-7NoR2-mZI%2Fbiorestorative-therapies-present-7th-international-conference-cell-therapy-cardiovascular-12973.html COMPANY TO DISCUSS THERMOSTEM™ PROGRAM ON METABOLIC DISORDERS AND OBESITY JUPITER, Fla., Jan. 23, 2012 /PRNewswire/ -- BioRestorative Therapies, Inc. (OTCQB: BRTX) ("BRT") today announced that it will be presenting at the Seventh International... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5621706 Mon, 23 Jan 2012 19:01:10 +0100 5621706 http://www.medworm.com/index.php?rid=5621707&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FLgqcjUABP2c%2Fventirx-pharmaceuticals-publishes-preclinical-data-novel-tlr8-agonist-vtx-2337-supporting-potential-12972.html Preclinical Data Published in Clinical Cancer Research Underscores Important Differences between TLRs in Human Immune Responses     SEATTLE, Jan. 23, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5621707 Mon, 23 Jan 2012 17:01:46 +0100 5621707 http://www.medworm.com/index.php?rid=5621709&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FzCp7bksycpE%2Fexelixis-reports-positive-preliminary-phase-2-cabozantinib-data-patients-hepatocellular-carcinoma-12971.html Data Highlight Progression Free Survival of 4.2 months in both sorafenib-pretreated and -naïve patients SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan 20, 2012 - Exelixis, Inc. (NASDAQ:EXEL) today reported positive preliminary data from the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5621709 Fri, 20 Jan 2012 20:01:49 +0100 5621709 http://www.medworm.com/index.php?rid=5621708&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FewDmOkpHHNc%2Finfinity-reports-new-data-phase-1b-trial-saridegib-patients-pancreatic-cancer-asco-gi-12970.html – Infinity to Review Saridegib Development Program on January 31, 2012, in New York City – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 20, 2012 - Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updated data from the Phase 1b portion... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5621708 Fri, 20 Jan 2012 20:01:49 +0100 5621708 http://www.medworm.com/index.php?rid=5612244&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F81yhp53OW5A%2Fimproves-survival-colorectal-cancer-patients-trial-results-show-12968.html ROCHESTER, Minn.--(BUSINESS WIRE)--Jan 17, 2012 - An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612244 Thu, 19 Jan 2012 17:01:54 +0100 5612244 http://www.medworm.com/index.php?rid=5612245&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FpqexM9Waewk%2Fphase-iii-data-show-bayer-s-investigational-compound-regorafenib-bay-73-4506-met-primary-endpoint-12969.html Pivotal trial data to be presented for the first time at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) ASCO-GI, LBA #385 WAYNE, N.J., Jan. 17, 2012 /PRNewswire/ -- Bayer HealthCare... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612245 Thu, 19 Jan 2012 17:01:44 +0100 5612245 http://www.medworm.com/index.php?rid=5612246&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fsg8XBuwE1nA%2Fcannabis-science-updates-second-medical-cannabis-cancer-patient-suffering-squamous-cell-carcinoma-12967.html DENVER--(BUSINESS WIRE)--Jan 19, 2012 - Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is very pleased to announce that the second patient suffering from basal... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612246 Thu, 19 Jan 2012 16:01:33 +0100 5612246 http://www.medworm.com/index.php?rid=5612247&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FHZlG02NKA1U%2Fpregnant-women-develop-threatening-blood-clots-should-receive-aggressive-research-iset-2012-shows-12965.html MIAMI BEACH, Fla.--(BUSINESS WIRE)--Jan 19, 2012 - Pregnant women who develop dangerous blood clots in the leg often forgo the most effective treatment for fear of harming the baby. Yet treatment to remove the clot is not only safe, it can... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612247 Thu, 19 Jan 2012 16:01:15 +0100 5612247 http://www.medworm.com/index.php?rid=5612248&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F0zBVSa4MN88%2Fcombination-oral-suppresses-common-type-hepatitis-c-according-university-michigan-led-research-12966.html     Researchers targeted the type of hepatitis C most common in the United States, results reported in New England Journal of Medicine   ANN ARBOR, Mich., January 19, 2012, 2012 /PRNewswire-USNewswire/ -- A new combination of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612248 Thu, 19 Jan 2012 16:01:14 +0100 5612248 http://www.medworm.com/index.php?rid=5612249&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FkJmx0uW3J9s%2Fresearchers-uncover-new-melanoma-accelerates-secondary-skin-cancers-12964.html LOS ANGELES, Jan. 18, 2012-Patients with metastatic melanoma taking the recently approved drug vemurafenib (marketed as Zelboraf) responded well to the twice-daily pill, but some of them developed a different, secondary skin cancer. Now,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612249 Thu, 19 Jan 2012 13:01:54 +0100 5612249 http://www.medworm.com/index.php?rid=5612250&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FUN2g8qLL0m0%2Foncogenex-announces-presentation-ogx-427-data-asco-2012-genitourinary-cancers-symposium-12963.html The Company to Host Investigator Panel and Reception to Review Clinical Data and Development Program BOTHELL, Wash. and VANCOUVER, British Columbia, Jan. 19, 2012  /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612250 Thu, 19 Jan 2012 13:01:10 +0100 5612250 http://www.medworm.com/index.php?rid=5612251&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FTRS1LR8RKEw%2Fprolor-biotech-announces-positive-top-line-results-pilot-study-long-acting-human-growth-hormone-12962.html -Post-Phase II hGH-CTP Study Shows Promise for Regimen in Which 2 hGH-CTP Injections Per Month Could Replace Current Regimen of 30 Growth Hormone Injections Per Month-- Nes-Ziona, Israel – January 18, 2012 – PROLOR Biotech, Inc. (NYSE Amex:... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612251 Wed, 18 Jan 2012 19:01:48 +0100 5612251 http://www.medworm.com/index.php?rid=5612252&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FxIT8qMi0diQ%2Fsoligenix-demonstrates-robust-stability-results-sgx204-anthrax-vaccine-12961.html Princeton, NJ - January 18, 2012 - Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from long-term stability studies of its proprietary DNI (dominant negative... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612252 Wed, 18 Jan 2012 16:01:56 +0100 5612252 http://www.medworm.com/index.php?rid=5612253&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FzoGyxymyg94%2Finflarx-announces-successful-conduct-clinical-phase-trial-ifx-1-new-monoclonal-antibody-inhibiting-12960.html JENA, Germany--(BUSINESS WIRE)--Jan 18, 2012 - InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612253 Wed, 18 Jan 2012 16:01:12 +0100 5612253 http://www.medworm.com/index.php?rid=5612254&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FOoff-1Ry2mg%2Fprolor-biotech-announces-positive-top-line-results-pilot-study-long-acting-human-growth-hormone-12959.html --Post-Phase II hGH-CTP Study Shows Promise for Regimen in Which 2 hGH-CTP Injections Per Month Could Replace Current Regimen of 30 Growth Hormone Injections Per Month-- NES-ZIONA, Israel, Jan. 18, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612254 Wed, 18 Jan 2012 13:01:21 +0100 5612254 http://www.medworm.com/index.php?rid=5612255&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F1Go7TA8JDRw%2Fhelps-maintain-platelet-inhibition-anti-clotting-levels-prior-cardiac-surgery-12958.html CHICAGO—Patients who discontinued use of an antiplatelet agent such as clopidogrel prior to undergoing cardiac surgery to lower their bleeding risk and received intravenously the platelet inhibitor cangrelor achieved a higher rate of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5612255 Wed, 18 Jan 2012 12:01:26 +0100 5612255 http://www.medworm.com/index.php?rid=5600127&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FNtXMVxWqwU4%2Fniiki-pharma-announces-completion-phase-escalation-first-man-anti-cancer-agent-nkp-1339-12955.html Trial Demonstrates Favorable Safety Profile with Anti-Tumor Activity HOBOKEN, N.J. and PHILADELPHIA, Jan. 17, 2012 /PRNewswire/ -- Niiki Pharma Inc. announced today that it has completed the dose escalation portion of the Phase I clinical trial of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600127 Tue, 17 Jan 2012 21:34:12 +0100 5600127 http://www.medworm.com/index.php?rid=5600128&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FiizYT05HWGA%2Fpv-10-mechanism-action-data-presented-society-surgical-oncology-annual-meeting-march-21-24-2012-12956.html KNOXVILLE, Tenn.--(BUSINESS WIRE)--Jan 17, 2012 - Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical data on the immunologic... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600128 Tue, 17 Jan 2012 21:21:16 +0100 5600128 http://www.medworm.com/index.php?rid=5600129&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fx41MZlOzwa8%2Fscripps-led-study-jama-shows-new-helps-bridge-stent-patients-cardiac-surgery-12957.html         SAN DIEGO , Jan. 17, 2012 /PRNewswire/ -- New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor has the unique properties of achieving very fast blood... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600129 Tue, 17 Jan 2012 21:10:45 +0100 5600129 http://www.medworm.com/index.php?rid=5600130&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FbzdY84QNptk%2Fbrainstorm-announces-clinical-data-supporting-safety-efficacy-nurown-based-initial-patient-results-12954.html NEW YORK & PETACH TIKVAH--(BUSINESS WIRE)--Jan 17, 2012 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that the data from... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600130 Tue, 17 Jan 2012 18:12:40 +0100 5600130 http://www.medworm.com/index.php?rid=5600131&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F8lcxoG3aFqM%2Fpevion-s-therapeutic-candida-vaccine-generates-functional-b-cell-memory-all-vaccinees-12946.html BERN, Switzerland, January 17, 2012/PRNewswire/ --Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100%... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600131 Tue, 17 Jan 2012 17:48:30 +0100 5600131 http://www.medworm.com/index.php?rid=5600132&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FREmrH1_UKks%2Ffirst-preclinical-proof-concept-mutation-based-individualized-cancer-vaccine-12947.html Deep sequencing of immunogenic mutations may pave way for customized immunotherapy   MAINZ, Germany, January 17, 2012/PRNewswire/ --The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600132 Tue, 17 Jan 2012 16:10:53 +0100 5600132 http://www.medworm.com/index.php?rid=5600133&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Ffx2WcbDfZ2c%2Fsynta-announces-publication-results-showing-ganetespib-synergizes-taxanes-multiple-non-small-cell-12952.html -Ganetespib and docetaxel display complementary cell cycle inhibition effects- -Combination of ganetespib with microtubule stabilizers (docetaxel and paclitaxel) or destabilizers (vincristine) results in synergistic anticancer activity- -Ganetespib... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600133 Tue, 17 Jan 2012 13:58:25 +0100 5600133 http://www.medworm.com/index.php?rid=5600134&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FbF870kq4p3U%2Fcolby-pharmaceutical-announces-publication-jvrs-100-potent-immune-activating-adjuvant-combination-12953.html SAN JOSE, Calif.--(BUSINESS WIRE)--Jan 9, 2012 - Colby Pharmaceutical Company (CPC) today announced publication of new results showing that a single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced-immune responses, -dose sparing,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600134 Tue, 17 Jan 2012 13:38:03 +0100 5600134 http://www.medworm.com/index.php?rid=5600135&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FvOP-OIC5zhU%2Farqule-announces-tivantinib-meets-primary-endpoint-significantly-extending-time-progression-phase-2-12948.html WOBURN, Mass.--(BUSINESS WIRE)--Jan 17, 2012 - ArQule, Inc. (NASDAQ: ARQL) today announced that treatment with tivantinib as single agent therapy produced a statistically significant 56 percent improvement in time-to-progression (TTP) in... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600135 Tue, 17 Jan 2012 13:07:16 +0100 5600135 http://www.medworm.com/index.php?rid=5600136&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FTmaxJuFRhiA%2Fmedivation-pfizer-announce-results-phase-3-concert-trial-dimebon-alzheimer-s-12949.html Dimebon Did Not Meet Primary Efficacy Endpoints SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)--Jan 17, 2012 - Medivation, Inc. (NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) today announced results from the CONCERT trial, which is a Phase 3 trial that... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600136 Tue, 17 Jan 2012 12:37:15 +0100 5600136 http://www.medworm.com/index.php?rid=5600137&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fborh3YmE2m4%2Fo-shot-may-improve-female-sexual-response-12950.html Multicenter Study Launched LA JOLLA, Calif., Jan. 17, 2012 /PRNewswire/ -- Using growth factors derived from a woman's own blood, physician researchers Drs. Samuel Wood and Charles Runels have developed a simple, office-based procedure that appears... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600137 Tue, 17 Jan 2012 12:16:01 +0100 5600137 http://www.medworm.com/index.php?rid=5600138&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FlBDYaykDs3M%2Frevive-trial-results-avanafil-published-jsm-demonstrate-significant-improvement-erectile-function-12951.html Results indicate low side effect rates with intercourse success reported by up to 71% of patients within 15 minutes of dosing MOUNTAIN VIEW, Calif., Jan. 17, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5600138 Tue, 17 Jan 2012 11:53:46 +0100 5600138 http://www.medworm.com/index.php?rid=5586139&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F0bM1PNcu_xA%2Fomthera-pharmaceuticals-announces-positive-long-term-bioavailability-data-comparing-epanova-lovaza-12945.html Epanova Increased EPA And DHA More than 5-Fold Compared to Lovaza After 2 Weeks of Dosing in 52 Subjects on A Low Fat Diet: Preliminary Data To Be Presented at J.P. Morgan Healthcare Conference In San Francisco On January 10, 2012 PRINCETON, N.J.,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586139 Fri, 13 Jan 2012 14:24:47 +0100 5586139 http://www.medworm.com/index.php?rid=5586140&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FMzXmfGo3hJA%2Fconventional-nerve-repair-wisdom-defied-first-ever-multicenter-clinical-study-processed-donated-12944.html     SAN FRANCISCO, Jan. 12, 2012 /PRNewswire-USNewswire/ --  In the first-ever multicenter clinical trial on processed nerve allograft, researchers from The Buncke Clinic in San Francisco found that treatment of severed peripheral... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586140 Thu, 12 Jan 2012 17:01:15 +0100 5586140 http://www.medworm.com/index.php?rid=5586141&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FtpHsXxyQT4M%2Fresearchers-find-first-major-gene-mutation-associated-hereditary-prostate-cancer-risk-12943.html Discovery may provide clues on disease development and who may need earlier screening ANN ARBOR, Mich., Jan. 11, 2012 /PRNewswire-USNewswire/ -- After a 20-year quest to find a genetic driver for prostate cancer that strikes men at younger... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586141 Thu, 12 Jan 2012 15:01:05 +0100 5586141 http://www.medworm.com/index.php?rid=5586142&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FFJUVot23L_0%2Fsynta-pharmaceuticals-university-toronto-researchers-elucidate-elesclomol-mechanism-action-using-12942.html -Results support elesclomol results seen in human clinical trials- -Elesclomol clinical trials on-going in acute myeloid leukemia and ovarian cancer- LEXINGTON, Mass.--(BUSINESS WIRE)--Jan 12, 2012 - Synta Pharmaceuticals Corp. (NASDAQ: SNTA)... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586142 Thu, 12 Jan 2012 14:01:13 +0100 5586142 http://www.medworm.com/index.php?rid=5586143&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FuqfIcxpdul8%2Fresearch-rare-genetic-poised-provide-new-therapies-according-new-white-paper-tuberous-sclerosis-12941.html SILVER SPRING, Md., Jan. 11, 2012 /PRNewswire-USNewswire/ -- A new white paper from the Tuberous Sclerosis Alliance (TS Alliance), entitled Unlocking a Cure for Tuberous Sclerosis Complex: An Assessment of Scientific Progress and Research Needs,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586143 Wed, 11 Jan 2012 20:23:02 +0100 5586143 http://www.medworm.com/index.php?rid=5586144&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FXIY61HbcNpY%2Fember-therapeutics-announces-nature-publication-brown-fat-biology-data-program-exclusively-licensed-12940.html Novel Hormone Identified that Augments Brown Fat, Increases Energy Expenditure, and Reduces Obesity and Insulin Resistance BOSTON--(BUSINESS WIRE)--Jan 11, 2012 - Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586144 Wed, 11 Jan 2012 18:01:11 +0100 5586144 http://www.medworm.com/index.php?rid=5586145&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FWyhPBcU6HFE%2Fcannabis-science-reports-apparent-success-3rd-self-medicated-cancer-patient-12939.html COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Jan 11, 2012 - Cannabis Science, Inc. (OTCBB: CBIS.OB - News), a pioneering US biotech company developing pharmaceutical cannabis products, is happy to report an additional, apparently successful,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586145 Wed, 11 Jan 2012 17:01:14 +0100 5586145 http://www.medworm.com/index.php?rid=5586146&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FUo-LockREWM%2Fpotential-role-natural-alkaloids-combatting-memory-loss-12938.html GLEN ALLEN, Va., Jan. 11, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: CIGX) - A study released in the January 9th issue of the Journal of Neurology suggests that nicotine patches may help individuals with early memory loss. Dr. Paul... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586146 Wed, 11 Jan 2012 16:01:07 +0100 5586146 http://www.medworm.com/index.php?rid=5586147&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fpi5IZc0T8xo%2Fspherix-announces-successful-completion-important-toxicology-study-spx-106-12937.html         Readies IND Filing BETHESDA, Md., Jan. 11, 2012 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586147 Wed, 11 Jan 2012 15:01:17 +0100 5586147 http://www.medworm.com/index.php?rid=5586148&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FNQVW8XLqgNs%2Fvical-provides-updates-cmv-vaccine-programs-12936.html SAN DIEGO, Jan. 11, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the online publication of a new article1 in The Lancet Infectious Diseases detailing results from the company's completed Phase 2 proof-of-concept trial... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586148 Wed, 11 Jan 2012 13:01:25 +0100 5586148 http://www.medworm.com/index.php?rid=5586149&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FRm8LJ6JzwU0%2Fgastrointestinal-cancers-symposium-american-society-clinical-oncology-asco-gi-phase-iii-data-bayer-12935.html -- Late-breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012 WAYNE, N.J., Jan. 10, 2012 /PRNewswire/ -- Bayer HealthCare today announced that results from the Phase III CORRECT study will be... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586149 Tue, 10 Jan 2012 21:01:24 +0100 5586149 http://www.medworm.com/index.php?rid=5586150&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FEHuyJ7_BX6E%2Fachillion-reports-clinical-data-portfolio-protease-inhibitors-12934.html Once-daily ACH-1625 safe, well-tolerated and achieves 100% cEVR after 12 weeks of treatment Pilot study of ACH-1625 in HCV genotype 3 achieves maximal 3.68 log10 reduction ACH-2684 safe, well tolerated and achieves HCV genotype 1 maximal 4.63... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586150 Tue, 10 Jan 2012 20:01:37 +0100 5586150 http://www.medworm.com/index.php?rid=5586151&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fnyfa51tArAQ%2Fcivitas-therapeutics-announces-positive-results-clinical-study-cvt-301-inhaled-l-dopa-parkinson-s-12933.html Pharmacokinetic Profile in Phase 1 Study Supports use of CVT-301 in Managing Motor Fluctuations Associated with Parkinson’s Disease Chelsea, MA – January 6, 2012 – Civitas Therapeutics, Inc., a privately-held pharmaceutical... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586151 Tue, 10 Jan 2012 16:01:08 +0100 5586151 http://www.medworm.com/index.php?rid=5586152&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FiT3j7FknD6g%2Ftechulon-s-platform-demonstrates-effective-non-viral-dna-delivery-vivo-cardiac-study-12932.html Techulon Glycopolymers Deliver NF-κB Decoy to Mitigate Injury from Cardiac Ischemia BLACKSBURG, Va.--(BUSINESS WIRE)--Jan 10, 2012 - Techulon Inc., developer of low-toxicity DNA and RNA delivery technology, announced today that its platform... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586152 Tue, 10 Jan 2012 15:01:58 +0100 5586152 http://www.medworm.com/index.php?rid=5586153&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FIIZw7P5hqX4%2Flx4211-enhances-dpp-4-inhibition-patients-type-2-diabetes-12931.html Combination of LX4211 and DPP-4 Inhibitor Reduces Blood Sugar After Meals and Increases GLP-1 in Type 2 Diabetic Patients More than DPP-4 Inhibitor Alone                   THE WOODLANDS, Texas, Jan. 9, 2012 /PRNewswire/ --... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586153 Tue, 10 Jan 2012 14:01:33 +0100 5586153 http://www.medworm.com/index.php?rid=5586154&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FBz5NCzrtZVQ%2Fdabigatran-associated-increased-risk-acute-coronary-events-12930.html CHICAGO—The anticoagulant dabigatran is associated with an increased risk of myocardial infarction (heart attack) or acute coronary syndrome in a broad spectrum of patients when tested against some other medicines, according to a study... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586154 Tue, 10 Jan 2012 14:01:17 +0100 5586154 http://www.medworm.com/index.php?rid=5586155&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fp7QUwiV6kZM%2Fomthera-pharmaceuticals-announces-positive-long-term-bioavailability-data-comparing-epanova-lovaza-12929.html Epanova Increased EPA And DHA More than 5-Fold Compared to Lovaza After 2 Weeks of Dosing in 52 Subjects on A Low Fat Diet: Preliminary Data To Be Presented at J.P. Morgan Healthcare Conference In San Francisco On January 10, 2012 Princeton,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586155 Tue, 10 Jan 2012 13:01:23 +0100 5586155 http://www.medworm.com/index.php?rid=5586156&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FC2-hctU6jhE%2Fneuralstem-president-ceo-update-ongoing-als-nsi-189-major-depressive-disorder-trials-2012-biotech-12928.html ROCKVILLE, Md., Jan. 9, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announces that President and CEO Richard Garr will present at the 2012 Biotech Showcase in San Francisco on Tuesday, January 10, 1:45-3:00pm PT. Garr will serve on the... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586156 Mon, 09 Jan 2012 20:01:31 +0100 5586156 http://www.medworm.com/index.php?rid=5586157&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FpjTDWN3mqjQ%2Fbiocon-announces-positive-efficacy-data-novel-monoclonal-antibody-itolizumab-pivotal-psoriasis-study-12927.html BENGALURU, India & SAN FRANCISCO--(BUSINESS WIRE)--Jan 9, 2012 - Biocon (BSE:532523) (NSE:BIOCON) (ISIN:INE376G01013), Asia's premier biotechnology Company, today announced positive results from its Double Blind, Placebo Controlled, Phase... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5586157 Mon, 09 Jan 2012 17:01:58 +0100 5586157 http://www.medworm.com/index.php?rid=5573532&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FEquGCpFODgw%2Fpearl-therapeutics-announces-successful-completion-phase-2b-safety-efficacy-studies-copd-12926.html - Pearl on track to commence Phase 3 program in 2012 - REDWOOD CITY, Calif., Jan. 6, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the completion of two Phase 2b clinical studies of PT003, the Company's investigational... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5573532 Fri, 06 Jan 2012 21:01:41 +0100 5573532 http://www.medworm.com/index.php?rid=5573533&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fosl3WgOOpEQ%2Fcivitas-therapeutics-announces-positive-results-clinical-study-cvt-301-inhaled-l-dopa-parkinson-s-12925.html Pharmacokinetic Profile in Phase 1 Study Supports use of CVT-301 in Managing Motor Fluctuations Associated with Parkinson's Disease CHELSEA, Mass.--(BUSINESS WIRE)--Jan 6, 2012 - Civitas Therapeutics, Inc., a privately-held pharmaceutical... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5573533 Fri, 06 Jan 2012 18:01:26 +0100 5573533 http://www.medworm.com/index.php?rid=5562917&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FZerEGRwtiA8%2Fdurect-announces-top-line-data-besst-posidur-u-s-pivotal-phase-iii-trial-12924.html Conference call to be held January 6 at 8:30 a.m. ET CUPERTINO, Calif., Jan. 5, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today top-line results from the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562917 Thu, 05 Jan 2012 21:01:47 +0100 5562917 http://www.medworm.com/index.php?rid=5562918&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fvhijp5ZAWlI%2Fregenerx-receives-clinical-study-report-phase-2-dry-eye-trial-12921.html ROCKVILLE, Md.--(BUSINESS WIRE)--Jan 5, 2012 - RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) announced today that it has received the clinical study report for its recently completed Phase 2... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562918 Thu, 05 Jan 2012 20:01:07 +0100 5562918 http://www.medworm.com/index.php?rid=5562919&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fi3Wmold22og%2Ftekmira-s-lnp-technology-enables-alnylam-s-positive-aln-pcs-clinical-data-12923.html Vancouver B.C. – Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented positive preliminary results from its... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562919 Thu, 05 Jan 2012 19:01:52 +0100 5562919 http://www.medworm.com/index.php?rid=5562920&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fe5_n_Rlx7G8%2Forbusneich-s-genous-stent-achieves-good-comparable-clinical-outcomes-patients-discontinuing-dual-12922.html Twelve-Month Follow-Up Data from a Post-Hoc Analysis of the e-HEALING Registry Published in Catheterization and Cardiovascular Interventions HONG KONG, Jan. 5, 2012 /PRNewswire/ -- OrbusNeich today announced that 12-month follow-up data from a... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562920 Thu, 05 Jan 2012 19:01:39 +0100 5562920 http://www.medworm.com/index.php?rid=5562921&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FKiFkKvRPYl0%2Fgoff-hill-ltd-announces-cure-cancer-viral-diseases-12920.html   WORTHING, Barbados, Jan. 5, 2012 /PRNewswire/ -- Goff Hill Ltd., a pharmaceutical research development company, announces the exciting new cancer drug that causes the cancer tumor cells to completely disintegrate with one five (5) day... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562921 Thu, 05 Jan 2012 18:01:18 +0100 5562921 http://www.medworm.com/index.php?rid=5562922&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2Fo5cgmh-giQI%2Fmajor-milestone-achieved-phase-iia-clinical-trial-rheumatoid-arthritis-meets-endpoint-12919.html    Further demonstration of the excellent safety profile of the TNF-Kinoid     Identification of 2 doses and an administration schedule that are immunogenic     Evidence of therapeutic activity in patients who have lost response to... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562922 Thu, 05 Jan 2012 18:01:04 +0100 5562922 http://www.medworm.com/index.php?rid=5562923&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FyhoBLPBCKTw%2Ftetragenetics-g-some-formulated-influenza-vaccine-provides-strong-protection-against-h5n1-12918.html CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 5, 2012 - Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562923 Thu, 05 Jan 2012 16:01:23 +0100 5562923 http://www.medworm.com/index.php?rid=5562924&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FAof9MOWoLSw%2Fprofibrix-us-phase-ii-study-fibrocaps-meets-all-primary-secondary-endpoints-12917.html LEIDEN, The Netherlands & SEATTLE--(BUSINESS WIRE)--Jan 5, 2012 - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562924 Thu, 05 Jan 2012 11:01:15 +0100 5562924 http://www.medworm.com/index.php?rid=5562925&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FBjEhG3e2zw0%2Fdespite-international-concern-u-m-study-shows-2006-re-introduction-rotavirus-vaccine-not-linked-12916.html     Original vaccine pulled from marketplace in 1999 after association with bowel obstruction ANN ARBOR, Mich., Jan. 4, 2012 /PRNewswire-USNewswire/ -- After being pulled from the marketplace in 1999 after being associated with painful... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562925 Wed, 04 Jan 2012 19:01:59 +0100 5562925 http://www.medworm.com/index.php?rid=5562926&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F-VC41SNYejw%2Falnylam-reports-positive-preliminary-clinical-results-aln-pcs-rnai-therapeutic-targeting-pcsk9-12915.html – RNAi Therapeutic Achieves Robust Silencing of PCKS9 and Reductions of Over 50% in LDL Cholesterol, a Validated Clinical Endpoint – – Results Highlight Major Potency Improvements of Second-Generation Lipid Nanoparticle Platform in... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562926 Wed, 04 Jan 2012 16:01:39 +0100 5562926 http://www.medworm.com/index.php?rid=5562927&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F4E9PYsYxYEQ%2Foncogenex-announces-publication-phase-ii-custirsen-ogx-011-tv-1011-data-journal-thoracic-oncology-12914.html Data supports potential role of custirsen for the treatment of patients with advanced non-small cell lung cancer BOTHELL, Wash. and VANCOUVER, British Columbia, Jan. 4, 2012 /CNW/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562927 Wed, 04 Jan 2012 14:01:40 +0100 5562927 http://www.medworm.com/index.php?rid=5562928&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FZyBdkbE_3Gs%2Fcan-fite-biopharma-announces-successful-results-phase-ii-liver-cancer-study-cf102-study-achieved-12912.html PETAH-TIKVA, Israel--(BUSINESS WIRE)--Jan 3, 2012 - Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange announced... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562928 Tue, 03 Jan 2012 16:01:45 +0100 5562928 http://www.medworm.com/index.php?rid=5562929&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FSWkdy9-GOGA%2Fosiris-therapeutics-provides-update-groundbreaking-stem-cell-trial-type-1-diabetes-12911.html COLUMBIA, Md.--(BUSINESS WIRE)--Jan 3, 2012 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), today provided an update on its Phase 2 trial evaluating Prochymal, a formulation of adult mesenchymal stem cells (MSCs), in patients with newly diagnosed... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562929 Tue, 03 Jan 2012 16:01:42 +0100 5562929 http://www.medworm.com/index.php?rid=5562930&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FLRVNDe3JamI%2Fgenerex-subsidiary-antigen-express-provides-update-ae37-cancer-vaccine-s-clinical-regulatory-12913.html Positive interim results from Phase 2b breast cancer study of AE37 presented last month at a major scientific breast cancer conference enable update to clinical development & regulatory strategy and the potential for earlier completion of key... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562930 Tue, 03 Jan 2012 14:01:02 +0100 5562930 http://www.medworm.com/index.php?rid=5562931&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F4txqREI7Gwk%2Faveo-astellas-announce-tivozanib-successfully-demonstrated-progression-free-survival-superiority-12890.html TIVO-1 is the First Registration Trial to Compare an Investigational Agent to an Approved VEGF Therapy in First-line RCC AVEO Conference Call Today at 8:30 a.m. ET CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Jan 3, 2012 - AVEO Pharmaceuticals,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562931 Tue, 03 Jan 2012 12:01:37 +0100 5562931 http://www.medworm.com/index.php?rid=5553997&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FBxB8wEFrXKA%2Ftargeted-therapy-extends-progression-free-survival-patients-advanced-ovarian-cancer-12889.html PHILADELPHIA (December 28, 2011) – Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5553997 Thu, 29 Dec 2011 14:12:03 +0100 5553997 http://www.medworm.com/index.php?rid=5553998&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FCsVVouP8xIQ%2Fwatson-present-30th-annual-j-p-morgan-healthcare-conference-12888.html PARSIPPANY, N.J., Dec. 28, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5553998 Thu, 29 Dec 2011 13:17:33 +0100 5553998 http://www.medworm.com/index.php?rid=5553999&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FSEXAgSOZx64%2Fperegrine-provides-update-hcv-clinical-program-12887.html Preliminary Data From Phase II Study Shows Antiviral Activity and Positive Safety Profile at Both Bavituximab Doses Evaluated; Supporting Further Dosing and Combination Studies; Company to Seek Collaboration to Advance HCV Program While... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5553999 Thu, 29 Dec 2011 13:12:41 +0100 5553999 http://www.medworm.com/index.php?rid=5546272&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F_vzx8xJuuUw%2Fanalysis-does-not-support-genetic-test-before-anti-clotting-12886.html CHICAGO—Although the U.S. Food and Drug Administration (FDA) has recommended that a certain type of genetic testing (for the genotype CYP2C19) be considered before prescribing the drug clopidogrel to identify individuals who may be less... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5546272 Wed, 28 Dec 2011 13:07:17 +0100 5546272 http://www.medworm.com/index.php?rid=5546273&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FWsZEgKfPAqM%2Fmarinus-pharmaceuticals-experimental-epilepsy-shows-promise-open-label-extension-study-12885.html     BRANFORD, Conn., Dec. 21, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that its neurosteroid ganaxolone which is currently under study for the treatment of partial onset seizures... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5546273 Tue, 27 Dec 2011 20:12:59 +0100 5546273 http://www.medworm.com/index.php?rid=5562932&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FfQBio6_km7g%2Fmedtrack-unveils-partnering-tool-j-p-morgan-healthcare-conference-12894.html Partnering tools offer the potential to hold more focused, productive meeting NEW YORK, Dec. 21, 2011 /PRNewswire/ -- MedTRACK, an Informa business unit, and the world's leading provider of pharmaceutical-focused business intelligence, has... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562932 Tue, 27 Dec 2011 20:12:46 +0100 5562932 http://www.medworm.com/index.php?rid=5562933&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FXnXi2_mhrNI%2Farteriocyte-takes-lead-promoting-building-future-pipeline-women-stem-career-fields-12906.html CLEVELAND, Dec. 13, 2011 /PRNewswire/ -- Don Brown, CEO of Arteriocyte Cellular Therapies Medical Systems (Arteriocyte) and Terri Sandu, Executive Director of Hard Hatted Women (HHW), are combining efforts to raise awareness of opportunities for... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562933 Tue, 27 Dec 2011 16:12:10 +0100 5562933 http://www.medworm.com/index.php?rid=5562934&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FF71LEnfZJac%2Ftpi-presents-2nd-annual-onemed-china-forum-january-9th-2012-san-francisco-12892.html     CHENGDU, China, Dec. 23, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine,... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562934 Tue, 27 Dec 2011 14:12:13 +0100 5562934 http://www.medworm.com/index.php?rid=5546274&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FFRK-DfbWE68%2F22nd-century-group-announces-initial-results-smoking-cessation-trial-12884.html Results will help determine the optimal nicotine content for X-22 CLARENCE, N.Y.--(BUSINESS WIRE)--Dec 26, 2011 - 22nd Century Group, Inc. (OTCBB: XXII), a company focused on smoking cessation and tobacco harm reduction products, today... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5546274 Tue, 27 Dec 2011 14:12:09 +0100 5546274 http://www.medworm.com/index.php?rid=5562935&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FC4IJzLXPBd8%2Fchina-botanic-exhibits-all-natural-anti-depressant-products-66th-pharmchina-fair-12891.html     HARBIN, China, Dec. 27, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562935 Tue, 27 Dec 2011 13:12:11 +0100 5562935 http://www.medworm.com/index.php?rid=5546275&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FyvYJPvRnHks%2Fraptor-pharmaceutical-corp-provides-program-update-rp103-dr-cysteamine-nephropathic-cystinosis-12883.html On Track to File Marketing Applications in US and EU in the First Quarter of 2012 NOVATO, Calif., Dec. 21, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) announced today a program update for its... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5546275 Sun, 25 Dec 2011 23:12:24 +0100 5546275 http://www.medworm.com/index.php?rid=5539852&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FjpzlvbLnkCU%2Fbrisk-ps-study-investigational-compound-brivanib-hepatocellular-carcinoma-completed-12882.html PRINCETON, N.J.--(BUSINESS WIRE)--Dec 22, 2011 - Bristol-Myers Squibb Company (NYSE: BMY) today reported that the Phase III BRISK-PS (Brivanib Study in HCC Patients at Risk Post Sorafenib) clinical trial in patients with hepatocellular... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5539852 Thu, 22 Dec 2011 21:12:52 +0100 5539852 http://www.medworm.com/index.php?rid=5539853&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FuTLdmtrLh7I%2Fnoven-announces-phase-3-results-investigational-non-hormonal-therapy-vasomotor-12881.html MIAMI & NEW YORK--(BUSINESS WIRE)--Dec 22, 2011 - Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced top-line results from the first of two planned Phase 3 clinical studies evaluating... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5539853 Thu, 22 Dec 2011 20:12:52 +0100 5539853 http://www.medworm.com/index.php?rid=5539854&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FL5EjItDsXkQ%2Fchelsea-therapeutics-reports-topline-results-phase-ii-trial-droxidopa-fibromyalgia-12880.html CHARLOTTE, N.C., Dec. 22, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced results of a Phase II dose-finding study designed to evaluate the safety and determine the potential therapeutic dose range of... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5539854 Thu, 22 Dec 2011 20:12:45 +0100 5539854 http://www.medworm.com/index.php?rid=5539855&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FY2pl6o8XWkw%2Fcelldex-completes-accrual-cdx-011-phase-2b-emerge-study-advanced-breast-cancer-12879.html NEEDHAM, MA (December 21, 2011): Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it has completed accrual of the EMERGE study, a randomized Phase 2b study evaluating CDX-011 (glembatumumab vedotin) in patients with previously... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5539855 Thu, 22 Dec 2011 20:12:31 +0100 5539855 http://www.medworm.com/index.php?rid=5562936&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FhYLOxY6QMVg%2Fbasf-glaxosmithkline-merck-novartis-among-companies-schedule-partnering-sessions-ced-science-12907.html Early registration encouraged to secure limited opportunities DURHAM, N.C.--(BUSINESS WIRE)--Dec 13, 2011 - CED, the Southeast's largest entrepreneurial support organization, today opened registration for partnering sessions at the CED Life... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562936 Thu, 22 Dec 2011 18:49:30 +0100 5562936 http://www.medworm.com/index.php?rid=5527915&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2F2CJB4BV8BAY%2Fnuvilex-associate-s-patent-expansion-sets-stage-hiv-ebola-sars-virus-12877.html SILVER SPRING, Md.--(BUSINESS WIRE)--Dec 22, 2011 - Nuvilex, Inc. (OTCQB:NVLX), an emerging international biotechnology provider of cell and gene therapy solutions including encapsulation of live cells and services through their associate SG... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5527915 Thu, 22 Dec 2011 15:30:31 +0100 5527915 http://www.medworm.com/index.php?rid=5562937&cid=s_36544_34_f&fid=36544&url=http%3A%2F%2Ffeeds.drugs.com%2F%7Er%2FDrugscom-ClinicalTrials%2F%7E3%2FASN-lbf8pRE%2Fincrease-your-knowledge-site-start-up-costs-2nd-annual-state-clinical-development-cost-conference-12893.html Analysis on site start-up costs PHILADELPHIA--(BUSINESS WIRE)--Dec 22, 2011 - The ˜2nd Annual State of Clinical Development Cost Conference' hosted by USciences and sponsored by TTC will highlight a variety of detailed research... (Source: Drugs.com - Clinical Trials) Drugs.com - Clinical Trials clinical trials http://www.medworm.com/rss/comments.php?id=5562937 Thu, 22 Dec 2011 15:17:10 +0100 5562937